Design, synthesis, and evaluation of novel hydrazide and hydroxamate derivatives as potent antileukemic agents with preferential HDAC-2 inhibitory activity over class I isoform

of 5.23 µM. Western blot analyses in SEM cells revealed that the lead compound 7a bound to its intracellular target, resulting in an approximately 59% reduction in total HDAC-2 protein levels. Flow cytometry revealed that a significant reduction in HDAC-2 led to cancer cells being arrested at the key G2/M phase of the cell cycle, with 46.22% of cells detained there compared to merely 7.21% in untreated controls. Subsequent analysis using Annexin V/PI labeling demonstrated that this cell cycle arrest results in a significant elevation of programmed cell death, increasing total apoptosis to 31.12%, while maintaining non-specific necrosis at a minimal 4.29%. Taken together, these findings indicate that the 4-iodo-3-nitrophenyl compounds are effective tools for the targeted treatment of leukemia, displaying preferential HDAC-2 inhibitory activity among the evaluated class I isoforms.

Authors

Institutions

Publication Details

Journal
RSC Advances
Published
2026-11-18
DOI
https://doi.org/10.1039/d6ra08049a
Primary Topic
Histone Deacetylase Inhibitors Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Design, synthesis, and evaluation of novel hydrazide and hydroxamate derivatives as potent antileukemic agents with preferential HDAC-2 inhibitory activity over class I isoform

Abdullah Yahya Abdullah Alzahrani, Bahaa G. M. Youssif, Bandar A. Alyami, Fatma Elzahraa Ali et al.
1 links
RSC Advances
Histone Deacetylase Inhibitors Research
article

Design, synthesis, and evaluation of novel hydrazide and hydroxamate derivatives as potent antileukemic agents with preferential HDAC-2 inhibitory activity over class I isoform

Abdullah Yahya Abdullah Alzahrani, Bahaa G. M. Youssif, Bandar A. Alyami, Fatma Elzahraa Ali, Stefan Bräse, Anber F. Mohammed
article en

Abstract

of 5.23 µM. Western blot analyses in SEM cells revealed that the lead compound 7a bound to its intracellular target, resulting in an approximately 59% reduction in total HDAC-2 protein levels. Flow cytometry revealed that a significant reduction in HDAC-2 led to cancer cells being arrested at the key G2/M phase of the cell cycle, with 46.22% of cells detained there compared to merely 7.21% in untreated controls. Subsequent analysis using Annexin V/PI labeling demonstrated that this cell cycle arrest results in a significant elevation of programmed cell death, increasing total apoptosis to 31.12%, while maintaining non-specific necrosis at a minimal 4.29%. Taken together, these findings indicate that the 4-iodo-3-nitrophenyl compounds are effective tools for the targeted treatment of leukemia, displaying preferential HDAC-2 inhibitory activity among the evaluated class I isoforms.

RSC AdvancesVol. 16(50)
Karlsruhe Institute of Technology (DE), Najran University (SA), King Khalid University (SA), Assiut University (EG)
Karlsruhe Institute of Technology
Good health and well-being
Histone Deacetylase Inhibitors Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon